Aspirin dosing in cardiovascular disease prevention and management: an update

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Aspirin has a long history in cardiovascular disease (CVD) management.
• Established benefits exist for acute scenarios and secondary CVD prevention.
• Net benefits for primary CVD prevention are less clear and debated.

Purpose of the Study:

• To review the association between aspirin and CVD.
• To examine aspirin dosing in acute settings, primary, and secondary prevention.
• To provide an update on current evidence-based practices and guideline recommendations.

Main Methods:

• Literature review of clinical and epidemiological studies.
• Analysis of established clinical guidelines.
• Synthesis of recent evidence-based practice trends.

Main Results:

• Aspirin's efficacy is well-documented in acute CVD events and secondary prevention.
• Optimal aspirin dosage and net clinical benefit in primary prevention require individualized risk stratification.
• Ongoing debate exists regarding optimal dosing in specific acute and stable ischemic heart disease contexts.

Conclusions:

• Clinician-led risk assessment is crucial for determining net clinical benefit before initiating aspirin therapy.
• Current evidence supports aspirin use in secondary prevention and acute settings.
• Further clarification on optimal dosing strategies for various CVD scenarios is warranted.